Drug intelligence / Profile preview

Bezoar Antipyrotic Tablet

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Bezoar Antipyrotic Tablet is a Traditional Chinese Medicine (TCM) formulated as a tablet. It is primarily used for its antipyretic (fever-reducing) and anti-inflammatory properties, and has also demonstrated anti-bacterial functions against certain pathogens, including drug-resistant Staphylococcus aureus. The drug contains bezoar (Calculus Bovis) and is likely composed of other traditional Chinese herbal ingredients. It is a product marketed by Yantai Tianzheng Pharmaceutical Co., Ltd., which was acquired by Bohai Pharmaceuticals Group, Inc.

Other names: Bezoar Antipyretic Tablets

Beyond the preview

Go deeper on Bezoar Antipyrotic Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bezoar Antipyrotic Tablet.

Explore the full profile